Next-generation basal insulin glargine U300 introduced in Pakistan

Next generation basal insulin glargine U300, now introduced in Pakistan, works like the human body's natural insulin and helps control blood sugar along with diet and exercise. Since approved by FDA in 2015, the drug had earlier been introduced in many countries such as US, Canada, Russia, Japan and India.
The new basal insulin, designed to act over 24 hours, seeks to address this unmet need to improve the control of blood sugar in adults living with diabetes. It promises stable blood sugar control throughout day and night that gives dosage flexibility and empowerment to patients. The control of blood sugar levels in patients with diabetes remains sub-optimal with many patients on treatment not reaching their blood sugar level goals. Sanofi Pakistan country chair and general manager Asim Jamal said that Sanofi is proud of its century-long heritage in diabetes research and development. He said they had been empowering people living with diabetes in Pakistan for over 50 years through oral therapies and for over a decade with insulin therapies. They endeavour to bring innovative solutions to patients to improve their health while their team of dedicated diabetes educators strives to enable the patients manage their condition efficiently and live active and full lives. "We remain committed to bringing advanced therapies to Pakistan, delivering better health outcomes for people with diabetes," he said.
Dr Leszek Czupryniak, Professor at the Department of Diabetology and Internal Medicine, Medical University of Warsaw, Poland, said that nearly 50 percent of people living with diabetes remain uncontrolled. Despite the proven efficacy of insulin, ensuring effective titration and maintenance can be a challenge - mostly due to the risk of hypoglycemia - and the insulin launched in Pakistan provides a new option. "Insulin glargine U300 takes the benefits of insulin to the next level, thus providing physicians a better tool to empower their diabetic patients, offering them insulin with lowest risk of hypoglycemia and being the safest in reaching optimal glucose control," he said.-PR